Apotex's Ruxolitinib ANDA Filing Timeline
Apotex plans to file an abbreviated new drug application (ANDA) for generic ruxolitinib (Jakafi/Incyte) in the first half of 2025, targeting the 505(b)(2) pathway with its topical cream formulation.[1]
Why Target Ruxolitinib Now?
Ruxolitinib's core Orange Book patents expire in 2027, but formulation-specific patents extend protection, prompting challengers like Apotex to file Paragraph IV certifications. Apotex cites non-infringement and invalidity arguments for its cream version, used in dermatology for graft-versus-host disease.[2][3]
When Do Key Ruxolitinib Patents Expire?
- Oral Jakafi tablets: Composition patent US 7,598,257 expires December 2027; pediatric exclusivity adds 6 months to 2028.
- Topical Opzelura cream: Patents like US 10,456,396 run to 2038, but generics target earlier entry via litigation.
Full patent details at DrugPatentWatch.com/ruxolitinib.[4]
Other Generic Challengers and Launch Dates
- Sandoz filed ANDA in 2023, tentative approval for 2028 launch.
- Teva and Lupin plan filings by mid-2025, eyeing 90-day exclusivity if first-to-file.
Apotex joins ~12 challengers; first generic could launch post-30-month stay if Incyte loses suits.[2][5]
Market Impact and Risks
U.S. Jakafi sales hit $2.6B in 2023; generics could cut prices 80%. Litigation risks delay entry—Incyte settled with some challengers for 2031 launches. FDA tentative approvals signal progress but no guaranteed dates.[1][3]
Sources
[1] FiercePharma: Apotex eyes 2025 filing
[2] FDA Paragraph IV Database
[3] Incyte Q4 Earnings Call Transcript
[4] DrugPatentWatch.com
[5] BioPharma Dive: Generic Pipeline